Overview
Voyxact is approved by the U.S. Food and Drug Administration (FDA) to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. This approval is based on the drug’s ability to reduce proteinuria, not on evidence of long-term kidney function improvement. Continued approval may depend on results from additional clinical trials. Voyxact is also known by its drug name, sibeprenlimab-szsi.

Voyxact is an A proliferation-inducing ligand (APRIL) blocker. It is believed to work by reducing the production of immunoglobulin A (IgA) antibodies that contribute to kidney inflammation and damage in people with IgAN.

How do I take it?
Prescribing information states that Voyxact is given as a subcutaneous (under the skin) injection once every four weeks. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Voyxact include upper respiratory tract infection and injection site erythema (discoloration at the injection site).

Rare but serious side effects may include serious hypersensitivity reactions, immunosuppression, increased risk of infections, and complications from receiving live vaccines. Live vaccines are not recommended within 30 days before starting or during treatment with Voyxact.

For more information about this treatment, visit:

Voyxact (Sibeprenlimab-Szsi) Injection, for Subcutaneous Use — Otsuka America Pharmaceutical